ProfileGDS5678 / 1451418_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 66% 66% 65% 66% 68% 65% 66% 67% 66% 66% 65% 66% 66% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1333968
GSM967853U87-EV human glioblastoma xenograft - Control 23.9780866
GSM967854U87-EV human glioblastoma xenograft - Control 33.9611466
GSM967855U87-EV human glioblastoma xenograft - Control 43.9076665
GSM967856U87-EV human glioblastoma xenograft - Control 53.931466
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2062468
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.9977965
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9655666
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.0553467
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.9475266
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9501566
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9321765
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9816266
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.9658866